Archives: Agenda
Navigating Clinical Operations in Biotech’s Survival Mode 生物医药寒冬之下：如何驾驭临床运营的“生存模式”
- Building Cross-Functional Leadership: Developing “T-shaped” talent with end-to-end operational vision.
- Proactive Risk Management: Systematically anticipating and mitigating clinical trial risks.
- Strategic Partnership with CROs: Redefining sponsor-CRO collaboration beyond transactional outsourcing.
- From Trial Data to Market Value: Making clinical quality the cornerstone of biotech IPO credibility.
- 构建跨职能领导力： 培养具备端到端（全流程）运营视野的“T型”复合型人才。
- 前瞻性风险管理： 系统性地预测并缓解临床试验过程中的潜在风险。
- 与 CRO 的战略合作伙伴关系： 重新定义申办方与 CRO 的合作模式，摆脱单纯的“交易型外包“。
- 从试验数据到市场价值： 让临床质量成为生物医药企业 IPO（上市）公信力的基石。
From Trial back to Target: Innovative CNS Drug Development 神经系统源创新药开发 之 靶标发现与靶点验证
Chairperson’s closing remarks and Gala Dinner – Sponsorship Available 主席闭幕致辞 及 晚宴 （锦绣厅）
Forging a World-Class Hub of Biomedical Innovation 打造世界级生物医药创新高地
- Development of the biomedical industry in SIP
- Innovation ecosystem for biomedical industry in SIP
- 苏州工业园区（SIP）生物医药产业的发展历程与现状
- 苏州工业园区（SIP）生物医药产业的创新生态系统
END OF CONFERENCE 会议结束
Lunch and networking
Lunch and networking
PANEL DISCUSSION: Global Site Activation: Navigating Overseas Clinical Trial Applications 圆桌讨论：全球中心启动：海外临床试验申请的实务导航
- Understanding country-specific site application and approval requirements
- Reducing start-up timelines through effective planning and local partnerships
- Common challenges and pitfalls when activating sites across multiple regions
- Best practices for successful collaboration with investigators, sites, and regulators
- 了解各国特定的中心申请与审批要求。
- 通过有效规划和本地合作伙伴关系缩短启动时间。
- 跨多个区域启动中心时常见的挑战和陷阱。
- 与研究者、中心和监管方成功协作的最佳实践
Moderator:
Julia Leng Multitude Therapeutics
Platform Strategies: Designing Flexible Supply Chains for Multi-Modality Trials 平台化策略：为多模态临床试验设计灵活的供应链
A single biopharma portfolio today may encompass a diverse mix of modalities—small molecules, monoclonal antibodies, ADCs, cell therapies, and more—each with vastly different and often contradictory supply chain requirements. This new reality demands a fundamental shift towards platform-based supply chain strategies.
- What Are We Actually Building?
- Orchestrating Complexity with Data & AI
- From Transactional Vendors to Strategic Capability Partners
- Upskilling Teams for a Multi-Modality World
如今，单一生物医药企业的研发管线可能涵盖多种不同的药物模态——小分子、单克隆抗体（单抗）、抗体偶联药物（ADCs）、细胞疗法等。这些药物对供应链的要求截然不同，甚至相互冲突。这一新现状要求供应链管理必须发生根本性转变，全面走向平台化策略。
- 我们究竟在构建什么？
- 利用数据与人工智能（AI）协调整合复杂流程
- 从传统的交易型供应商转型为战略能力合作伙伴
- 赋能团队升级，全面迎接多模态时代